ArticleCancer research communications2026
Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial.Nature medicine · 2026Article
- Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study.Nature medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Multi-cancer early detection (MCED) tests represent a significant technological advancement, allowing for the detection of multiple cancers through a single screening test. In December 2023, Dana-Farber Cancer Institute (DFCI) initiated an MCED clinical and research program to serve patients receiving positive MCED test results and further study MCED tests in clinical practice. Prospective case series reporting on patients with a signal detected by the Grail Galleri MCED test who presented for diagnostic evaluation at DFCI between December 2023 and January 2025. Primary outcomes were confirmation of cancer diagnosis, time to diagnostic resolution, and accuracy of the cancer signal origin (CSO) suggested. Of the 14 patients with a positive MCED test, 78.6% had a confirmed cancer diagnosis, whereas 21.4% were false positives. The median age was 62.5 years, with 64.3% male and 85.7% White, non-Hispanic. The median time from MCED test result to presentation at the DFCI MCED clinic was 28 days. The median time from MCED clinic presentation to diagnostic resolution was 20 days. Among confirmed cases, 54.5% were solid tumors and 45.5% were hematologic malignancies. More than 90% of detected malignancies lack current screening guidelines. Six cancers were diagnosed at stage I/II, and five at III/IV. Most patients with a cancer signal detected on a MCED test were true positives with a cancer consistent with the CSO reported. Patients had their MCED test results quickly adjudicated when presenting to a dedicated clinical program supporting a role for cancer diagnostic expertise in evaluating MCED tests. SIGNIFICANCE: MCED tests are a new and evolving technology that may help detect cancer early on. Here, we report the experience of a dedicated cancer clinic in evaluating patients with a positive cancer signal from an MCED test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.